Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSCs for Refractory Acute GVHD
NCT06304025Phase 2Not yet recruiting
- Sponsor
- FOSCAL
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of wharton's jelly mesenchymal stromal cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by FOSCAL. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06304025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304025.